A Study to Evaluate Features of KN069 in Participants With Obesity or Overweight

Summary

This is a Phase 1, First-in-human, double-blinded, placebo-controlled study which aims to investigate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the immunogenicity of KN069 in Chinese male participants with Obesity or Overweight.

Timeline

Start

2024-08-02

Primary completion

2027-04-30

Completion

2027-06-30

Publications

• Xie J, Huang J, Wu Q, Deng K, Yang S, Yang S, Wu S, Yang X, Huang W, Dong Y, Li J, Yang G, Guo C. A Phase 1, Randomised, Double-Blind, Placebo-Controlled Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of KN069 (a Dual GLP-1R Agonist and GIPR Antagonist) in Male Adults With Overweight or Obesity. Diabetes Obes Metab. 2026 Jul;28(7):5848-5859. doi: 10.1111/dom.70794. Epub 2026 Apr 20.

Drugs

Indications